MSB 2.03% $1.45 mesoblast limited

No it is not the correct interpretation.Company guidance was as...

  1. 2,978 Posts.
    lightbulb Created with Sketch. 2116
    No it is not the correct interpretation.

    Company guidance was as below- no time frame- they have now , as per last presentation, said second half of the year.

    Mesoblast intends to request a pre-BLA meeting with FDA to discuss data presentation, timing and
    FDA expectations for an accelerated approval filing in ischemic HFrEF patients with end-stage heart
    failure.


    Come back July 1


    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.